Call Us      +44 (0)20 70961222



11th June 2018 | The Sheraton, Boston Harbour


The Biomanufacturing Roundtable Discussions strategy meeting are for qualified end-users. Senior Executives of Biomanufacturing and Bioprocessing (from medium to large Pharma, Biopharma and Biotech players) as well as thought leaders from Academia and regulatory authorities.

Thought leaders who will benefit from attending includes: Chief Executive Officers, Executive Vice President, Senior Vice President, Vice President, Executive Directors, Directors Global Heads responsible for: Process R&T/R&D/Development & Engineering, Upstream Drug Substance Development and Technology Management, Cell Culture Manufacturing/Cell Line Engineering, Purification Development, Preclinical Manufacturing, Technology and Standardisation, Quality Operations/Quality Sciences Compliance and Analytical Technology, Validation Manufacturing Science,Risk Management, Bioprocessing R&D Analytics, CMC, Early Stage Bioprocess Development, Product Supply.

Those who do not qualify for VIP passes, including vendors, exchanges, consultancies and other service providers, can apply here.

Formal Portrait of Mike Thien

Michael Thien

Senior Vice President and Head, Biologics and Sterile Operations



Christie Bielinski

Vice President Product Quality Management

Johnson & Johnson


Stephanie Krogmeier

Vice President, Global Regulatory Affair

Vertex Pharmaceuticals

Gregory Zarbis-Papastoitsis (2)

Gregory Zarbis Papastoitsis

Vice President of Process & Manufacturing

Compass Therapeutics

Melissa Seymour.jpg (1)

Melissa Seymour

Vice President Global Quality Control



John Ruesch

Vice President Protein Development


Paul Logue (1)

Paul Logue

Vice President, Biologics

Sanofi Genzyme

Vijay (1)

Vijay Yabanavar

Vice President, Global Technical Operations


Interactive Roundtable Discussions

Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.

one to one copy
Director level one-to-one meetings

We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.

Tailor-fit and Personalized Agenda

Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.

netwkorking copy
Networking Opportunities

Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.

Thank you for reaching Proventa International

One of our executives will contact you within 24 hours



***The information you provided in this website is confidential and the company will strictly forbidden to share any part of these information with any third party without a written consent of the sender.


If you are an exciting start-up trying to get your innovation in front global heads from the leading Pharmaceutical companies, or a mature market-leading conglomerate with legacy solutions trying to stay one step ahead of the competition – we are here to help!


Pharma Supply Chain EU 2016 ,  Return on Investment attained at the meeting and why they are coming back

Pharma Supply Chain EU 2016 , Return on Investment attained at the meeting and why they are coming back

Pharma Supply Chain EU 2016 , What they think of the roundtable discussion format

Pharma Supply Chain EU 2016 , Level of delegation, attendee diversity and seniority

Pharma Supply Chain EU 2016 , What they think of the 1-1 prequalified business meetings

Samuel T. Labrie, VP Corporate Development, Myriad RBM

Kam Dhaliwal, SVP Services & Alliances, Horizon Discovery

Matt Hersch, Clinical Operations Manager, GW Pharmaceuticals

Rainer Metzger, VP Global Business Development Pharma, Qiagen

Dilsaid Babayigit, Founder & CEO, Ageneo

John Apathy, Vice President, R&D informatics, Celgene

Lars Branden, Senor Director,Informatics R&D Division,Retro Screen Virology Ltd.

Dominic Clark , Industry Programme Manager,EMBL-EBI

Yike Guo, Director Data Science Institude, Imperial College London

John Wise, Executive Director, Pistoia Alliance

Abel Ureta-Vida, CEO, Eagle Genomics

Alexander Scheer, Deputy Head of Research, Pierre Fabre

Jerome Wojcik , CEO,Quartz Bio

Oleksandr Otava, Head Of Scientific IT, Affiris AG

Sowmyanarayan Srinivasan, Director R&D Practise,Global Delivery Leader Discovery

Yaron Turpaz

Chief Information Officer

Its nice because they basically allowed people to engaged to discussions and questions. Academic and industry is very nice and informative

Ivan John Clement

Data Scientist - R&D

Its good because you really get the people to talk. They are willing to share their knowledge, the juniors are very eager to learn.

Raghuraman Gopal

Manager Quality Assurance

The format is the beginning of breakthrough and integration, the level of delegates is very good and excellent, they learn a lot.

Dadabhai Singh

Founder & President

The kind of interaction is very interactive

Steve Rozen

Director & Professor

Because of diversity we really districts the points and all. People are very diversity and thoughtful in a round table.

Images coming soon




39 Dalton St, Boston, MA 02199, USA


+1 617-236-2000


Gregory Zarbis-Papastoitsis (2)

Gregory Zarbis-Papastoitsis

Vice President of Process & Manufacturing

Compass Therapeutics



 Christie Bielinski,

Vice President Product Quality and Management

Johnson & Johnson,


Vijay (1)

Vijay Yabanavar,, Vice President, Global Technical Operations - Vaccines, Biologics, Therapeutic Proteins and Sterile Operations


Dr. Yabannavar is a senior executive with 30 years of experience in process & product development, manufacturing and project leadership spanning biopharmaceuticals (including antibodies) and vaccines areas at Schering-Plough, Chiron, Novartis, Trubion/Emergent Biosolutions and Merck.  Currently VP of Global Technical Operations – Vaccines, Biologics & Sterile Operations at Merck (West Point, PA). Dr. Yabannavar received his Ph.D. in (Bio)Chemical Engineering from MIT in 1988. He has made 22 conference presentations, published 10 papers and 2 patents. He chaired the Biochemical Engineering XV Conference (Quebec City, Canada) in 2007.  He has served as a member of the Advisory Board for the Chemical Engineering and Materials Science Department at U. California, Davis (Davis, CA).

Paul Logue (1)

Paul Logue

Vice President, Biologics





Michael Thien

Senior Vice President and Head, Biologics and Sterile Operating Unit, Merck

Dr. Thien has worked in new product and process development and operations at Merck for over 25 years. Mike joined the Merck Research Labs, working in vaccines and recombinant proteins. From 1991 through 2004, Dr. Thien held positions in process development of increasing responsibility, culminating in his being named a VP of process development in 2003.

From 2005 to 2017, Mike’s responsibilities increased to include late stage development, launch and in-line product support for small molecules, therapeutic proteins and vaccines, as well as being responsible for commercial manufacturing operations in Singapore, Ireland and Puerto Rico and was appointed Senior Vice President of Global Science, Technology and Commercialization. In 2017, Mike was named as head of the end to end Operating Unit for Biologics and Sterile Operations, including leadership of both internal and external commercial manufacturing networks for biologics and sterile operations and late development and in-line support for biologics, vaccines and sterile operations.


John Ruesch,

Vice President Protein Development


John has over 20 years of experience in pharmaceutical and biopharmaceutical development. Prior to joining Biogen, John was Senior Director, Protein Formulation & Process Development at Pfizer.. He has held multiple positions including Sr. Director, Analytical Development and Sr. Director, Quality Control, Stability and Microbiology, and Quality Assurance Lead for Sterile Parental Products as well as many other quality and technical roles.  John received his B.S. in Biology from Valparaiso University and his Executive MBA from Kellogg School of Management at Northwestern University.


Over the past 20 years there have been tremendous advancements in the technology, understanding and control of cell culture. Is the current technology and understanding good enough?  Some of the challenges are listed below that the industry is facing.

Melissa Seymour.jpg (1)

Melissa Seymour

Vice President Global Quality Control



Melissa Seymour is the Vice President of Global Quality Control for Biogen, Inc., assuming responsibility for the comprehensive strategy and implementation for Global QC testing of Raw Materials, Drug Substance, Drug Product and Finished Goods worldwide.   Prior to this, Melissa served as the Vice President of Corporate Quality with responsibility for global compliance and quality systems including management of Quality Systems, Internal and External Auditing and Global Affiliate GMP oversight. Melissa holds BS degrees in both Biological Sciences and Biochemistry from North Carolina State University and an executive MBA from Duke University.  Melissa has over 20 years of experience in the quality arena including quality positions at Novo Nordisk pharmaceuticals and Glaxo Smith Kline. Melissa is a member of the Board of Directors for PDA as well as and Interest Group leader for Tech Transfers and a core member of the PDA PAC iAM Task Force. Melissa is an ASQ Certified Quality Engineer, Certified Quality Auditor and Certified Quality Manager and has previously served on the Board of Directors for the Rx-360 Consortium focused on supply chain security.


Stephanie Krogmeier

Vice President, Global Regulatory Affairs, Vertex Pharmaceuticals

Stephanie Krogmeier has been with Vertex Pharmaceuticals in Boston, MA for 13 years. Stephanie earned a Ph.D. in Pharmaceutical Chemistry from the University of Kansas. Previously she earned a B.S. in Pharmacy from Drake University. Stephanie began her career at Vertex in Formulation Development before she moved into Global CMC Regulatory Affairs. Stephanie has led the CMC preparation of multiple marketing applications which have included QbD strategies, drug product continuous manufacturing processes and real time release testing strategies. Stephanie is currently the Vice President of Global CMC Regulatory Affairs Strategy at Vertex and continues to pursue innovate CMC regulatory strategies.